Contracts › 75N91020F00009
75N91020F00009: On Behalf of Niaid-Dcr, Facilitate the Conduct of Two, Randomized Trials As Detailed Below in I and Ii: I. a Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of Covid-19 (2,000 Subjects
Awarded to Leidos Biomedical Research Inc by National Institutes of Health (NIH).
$89.6Mobligated
$136.7Mpotential value
31 July 2028current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N91020F00009 |
|---|---|
| Vehicle | 75N91019D00024 |
| Awardee | Leidos Biomedical Research Inc |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NIH NCI |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | MD |
| Period of performance | 01 April 2020 to 31 July 2028 |
| Potential end | 31 July 2028 |
| Estimated recompete solicitation | ~Q1 2028 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record